$0.19
5.48% day before yesterday
Nasdaq, Dec 27, 10:07 pm CET
ISIN
US55234L1052
Symbol
LYRA
Sector
Industry

Lyra Therapeutics Inc Stock price

$0.19
+0.00 0.26% 1M
-0.07 27.07% 6M
-5.05 96.36% YTD
-4.91 96.26% 1Y
-4.45 95.89% 3Y
-18.37 98.97% 5Y
-18.37 98.97% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 5.48%
ISIN
US55234L1052
Symbol
LYRA
Sector
Industry

Key metrics

Market capitalization $12.47m
Enterprise Value $-3.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.05
EV/Sales (TTM) EV/Sales -2.61
P/S ratio (TTM) P/S ratio 8.48
P/B ratio (TTM) P/B ratio 0.60
Revenue growth (TTM) Revenue growth 3.37%
Revenue (TTM) Revenue $1.47m
EBIT (operating result TTM) EBIT $-67.44m
Free Cash Flow (TTM) Free Cash Flow $-80.90m
Cash position $51.63m
EPS (TTM) EPS $-1.53
P/E forward negative
P/S forward 8.23
EV/Sales forward negative
Short interest 4.20%
Show more

Is Lyra Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Lyra Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Lyra Therapeutics Inc forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Lyra Therapeutics Inc forecast:

Buy
20%
Hold
80%

Financial data from Lyra Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.47 1.47
4% 4%
100%
- Direct Costs 0.41 0.41
-
28%
1.07 1.07
-
73%
- Selling and Administrative Expenses 19 19
1% 1%
1,282%
- Research and Development Expense 49 49
10% 10%
3,352%
-67 -67
7% 7%
-4,561%
- Depreciation and Amortization 0.41 0.41
-
28%
EBIT (Operating Income) EBIT -67 -67
7% 7%
-4,588%
Net Profit -98 -98
58% 58%
-6,640%

In millions USD.

Don't miss a Thing! We will send you all news about Lyra Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyra Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --   Lyra Therapeutics, Inc.  (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Neutral
GlobeNewsWire
2 months ago
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult p...
Neutral
GlobeNewsWire
3 months ago
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company's lead produ...
More Lyra Therapeutics Inc News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Head office United States
CEO Maria Palasis
Employees 88
Founded 2005
Website www.lyratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today